Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02381236 · ClinicalTrials.gov registry record · Phase 2
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
A Phase 2 study of Prostatic Neoplasms, sponsored by GenSpera.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT02381236: Completed Phase 2 study of Prostatic Neoplasms, sponsored by GenSpera.
NCT02381236 is a Phase 2 study of Prostatic Neoplasms that has completed, run by GenSpera. The registered enrollment target is 1 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02381236, a Phase 2 study of Prostatic Neoplasms, has completed, sponsored by GenSpera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
Primary Outcome
mpMRI performed after 3 cycles of treatment prior to prostatectomy
Conditions Studied
Interventions
- DRUG G-202
Study Locations (1)
Texas
- University of Texas Health Sciences Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
What the finished NCT02381236 record still lists
NCT02381236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which G-202 is the first listed.
NCT02381236 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02381236 about?
NCT02381236 is a clinical study titled "G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer". A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
What is the current status of trial NCT02381236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-02. Estimated completion is 2017-02.
What conditions does trial NCT02381236 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02381236?
The interventions under investigation include: G-202 (DRUG).
Who is sponsoring clinical trial NCT02381236?
This trial is sponsored by GenSpera, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02381236 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02381236's enrollment target sits among peer trials
1 66th of 65 the lowest of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
RECRUITING · Phase 2
-
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
RECRUITING · Phase 2
-
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia